Janux Therapeutics (NASDAQ:JANX) Shares Gap Down to $64.78

Janux Therapeutics, Inc. (NASDAQ:JANX) gapped down prior to trading on Monday . The stock had previously closed at $64.78, but opened at $63.16. Janux Therapeutics shares last traded at $58.63, with a volume of 209,126 shares changing hands.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on JANX. William Blair restated an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday, February 27th. Wedbush restated an “outperform” rating and issued a $53.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 11th. Jonestrading assumed coverage on Janux Therapeutics in a research note on Tuesday, April 16th. They set a “buy” rating and a $70.00 target price for the company. BTIG Research started coverage on Janux Therapeutics in a report on Thursday, March 21st. They set a “buy” rating and a $62.00 price target for the company. Finally, Bank of America upped their price objective on shares of Janux Therapeutics from $24.00 to $48.00 and gave the company a “buy” rating in a report on Wednesday, March 13th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $61.33.

Janux Therapeutics Stock Down 3.6 %

The company has a market capitalization of $3.08 billion, a P/E ratio of -45.90 and a beta of 3.87. The company’s fifty day moving average price is $45.03 and its 200 day moving average price is $22.15.

Janux Therapeutics (NASDAQ:JANX) last released its earnings results on Friday, March 8th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.12. Janux Therapeutics had a negative return on equity of 17.88% and a negative net margin of 721.18%. The company had revenue of $2.46 million for the quarter, compared to analyst estimates of $0.98 million. Research analysts predict that Janux Therapeutics, Inc. will post -1.41 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC boosted its holdings in shares of Janux Therapeutics by 2,166.1% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 26,264 shares of the company’s stock valued at $282,000 after purchasing an additional 25,105 shares in the last quarter. Cerity Partners LLC acquired a new stake in Janux Therapeutics in the fourth quarter valued at about $654,000. Barclays PLC grew its position in Janux Therapeutics by 227.1% in the third quarter. Barclays PLC now owns 17,922 shares of the company’s stock valued at $181,000 after acquiring an additional 12,443 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in Janux Therapeutics during the fourth quarter worth about $57,000. Finally, FMR LLC lifted its holdings in shares of Janux Therapeutics by 25.5% in the third quarter. FMR LLC now owns 6,351,322 shares of the company’s stock worth $64,021,000 after acquiring an additional 1,288,526 shares during the last quarter. 75.39% of the stock is owned by institutional investors.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.